BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND TRAF7, DKFZp586I021, 84231, ENSG00000131653, RNF119, MGC7807, Q6Q0C0, RFWD1
9 results:

  • 1. traf7-mutated Fibromyxoid Spindle Cell Tumors Are Associated With an Aggressive Clinical Course and Harbor an Undifferentiated Sarcoma Methylation Signature: A Molecular and Clinicopathologic Study of 3 Cases.
    Dermawan JK; Villafania L; Bale T; Singer S; D'Angelo SP; Tap WD; Antonescu CR
    Am J Surg Pathol; 2023 Feb; 47(2):270-277. PubMed ID: 36395468
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas.
    Jin L; Youngblood MW; Gupte TP; Vetsa S; Nadar A; Barak T; Yalcin K; Aguilera SM; Mishra-Gorur K; Blondin NA; Gorelick E; Omay SB; Pointdujour-Lim R; Judson BL; Alperovich M; Aboian MS; McGuone D; Gunel M; Erson-Omay Z; Fulbright RK; Moliterno J
    J Neurooncol; 2021 Sep; 154(2):237-246. PubMed ID: 34350560
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas.
    Schieffer KM; Agarwal V; LaHaye S; Miller KE; Koboldt DC; Lichtenberg T; Leraas K; Brennan P; Kelly BJ; Crist E; Rusin J; Finlay JL; Osorio DS; Sribnick EA; Leonard JR; Feldman A; Orr BA; Serrano J; Vasudevaraja V; Snuderl M; White P; Magrini V; Wilson RK; Mardis ER; Boué DR; Cottrell CE
    Am J Surg Pathol; 2021 Mar; 45(3):329-340. PubMed ID: 33074854
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
    Martinez NL; Khanna O; Farrell CJ
    Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
    Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
    J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
    Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
    Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.